Skip to main content
Premium Trial:

Request an Annual Quote

Crosslinks Joins InforSense Partner Network

NEW YORK (GenomeWeb News) – InforSense today announced that Dutch firm Crosslinks has joined the InforSense Open Partner Network as a certified provider of the firm’s technologies.
Through the alliance, Crosslinks becomes a preferred InforSense Services Provider in Europe for both academic and commercial customers. It also operates a demonstration center in the Netherlands for InforSense’s technology.
The InforSense platform will enable Crosslinks to fulfill growing demand for large-scale, genome-wide analyses, said Crosslinks CEO Ronald Nanninga in a statement. He said the firm would apply the technology to bioinformatics data analysis in research and diagnostic applications.
Crosslinks is a spinoff from the Erasmus MC Department of Bioinformatics and provides analysis of genomics and proteomics data.
Terms of the alliance were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.